Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics (Nasdaq: MNPR) has closed its previously announced public offering of common stock, raising $19.2 million in gross proceeds. The shares were priced at $16.25 per share. Notable participants included Janus Henderson Investors and RA Capital Management. Rodman & Renshaw served as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. The offering was made through a shelf registration statement previously filed with the SEC.
Monopar Therapeutics (Nasdaq: MNPR) ha concluso la sua offerta pubblica di azioni ordinarie precedentemente annunciata, raccogliendo 19,2 milioni di dollari in proventi lordi. Le azioni sono state prezzate a 16,25 dollari per azione. Tra i partecipanti importanti figurano Janus Henderson Investors e RA Capital Management. Rodman & Renshaw ha svolto il ruolo di agente di collocamento esclusivo. L'azienda prevede di utilizzare i proventi per scopi aziendali generali, tra cui ricerca e sviluppo, sperimentazioni cliniche, produzione di prodotti e capitale circolante. L'offerta è stata effettuata tramite una dichiarazione di registrazione a scaffale precedentemente depositata presso la SEC.
Monopar Therapeutics (Nasdaq: MNPR) ha cerrado su oferta pública previamente anunciada de acciones comunes, recaudando $19.2 millones en ingresos brutos. Las acciones se fijaron a $16.25 por acción. Los participantes notables incluyeron a Janus Henderson Investors y RA Capital Management. Rodman & Renshaw actuó como agente de colocación exclusivo. La empresa planea utilizar los ingresos para fines corporativos generales, incluyendo investigación y desarrollo, ensayos clínicos, fabricación de productos y capital de trabajo. La oferta se realizó a través de una declaración de registro en estante presentada anteriormente ante la SEC.
몬오파 테라퓨틱스 (Nasdaq: MNPR)은 이전에 발표한 공모주식 매각을 마감하고, 1920만 달러의 총 수익을 올렸습니다. 주가는 주당 16.25달러로 책정되었습니다. 주목할 만한 참여자로는 Janus Henderson Investors와 RA Capital Management가 있습니다. Rodman & Renshaw가 독점 배치 대행사로 활동했습니다. 회사는 수익금을 연구 및 개발, 임상 시험, 제품 제조 및 운영 자본을 포함한 일반 회사 용도로 사용할 계획입니다. 이번 공모는 SEC에 이전에 제출된 선반 등록 성명을 통해 이루어졌습니다.
Monopar Therapeutics (Nasdaq: MNPR) a clôturé son offre publique d'actions ordinaires déjà annoncée, levant 19,2 millions de dollars de recettes brutes. Les actions étaient fixées à 16,25 dollars par action. Les participants notables comprenaient Janus Henderson Investors et RA Capital Management. Rodman & Renshaw a servi d'agent de placement exclusif. L'entreprise prévoit d'utiliser les recettes pour des besoins d'entreprise généraux, y compris la recherche et le développement, les essais cliniques, la fabrication de produits et le fonds de roulement. L'offre a été réalisée par le biais d'une déclaration d'enregistrement sur étagère préalablement déposée auprès de la SEC.
Monopar Therapeutics (Nasdaq: MNPR) hat seine zuvor angekündigte öffentliche Aktienangebot abgeschlossen und 19,2 Millionen USD an Bruttoeinnahmen erzielt. Die Aktien wurden zu einem Preis von 16,25 USD pro Aktie angeboten. Zu den bemerkenswerten Teilnehmern gehören Janus Henderson Investors und RA Capital Management. Rodman & Renshaw fungierte als exklusiver Platzierungsagent. Das Unternehmen plant, die Einnahmen für allgemeine Unternehmenszwecke zu verwenden, einschließlich Forschung und Entwicklung, klinische Studien, Produktfertigung und Betriebskapital. Das Angebot wurde über eine zuvor bei der SEC eingereichte Shelf-Registrierungserklärung durchgeführt.
- Successfully raised $19.2 million in gross proceeds
- Attracted notable institutional investors including Janus Henderson and RA Capital Management
- Secured funding for R&D, clinical trials, and manufacturing operations
- Potential dilution of existing shareholders' equity
- Additional offering expenses and placement agent fees will reduce net proceeds
Insights
This
The pricing at
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of
Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.
Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.
Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.
The securities were offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by email at info@rodm.com, or by telephone at (212) 540-4414.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About Monopar Therapeutics
Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: statements regarding the anticipated use of proceeds from the offering. The forward-looking statements involve risks and uncertainties including, but not limited to: our ability to raise sufficient funds in order for us to support continued clinical, regulatory and commercial development of our programs and to make contractual upfront and future milestone payments, as well as our ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; uncertainties related to the regulatory discussions we intend to initiate related to ALXN-1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which we receive marketing approval, and our ability to competitively market any such products as compared to larger pharmaceutical firms; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
FAQ
What was the price per share in Monopar Therapeutics (MNPR) October 2024 public offering?
How much did Monopar Therapeutics (MNPR) raise in its October 2024 public offering?
Who were the major investors in Monopar Therapeutics (MNPR) October 2024 public offering?